R
Richard A. Rudick
Researcher at Biogen Idec
Publications - 264
Citations - 31960
Richard A. Rudick is an academic researcher from Biogen Idec. The author has contributed to research in topics: Multiple sclerosis & Interferon beta-1a. The author has an hindex of 76, co-authored 258 publications receiving 29504 citations. Previous affiliations of Richard A. Rudick include Cleveland Clinic Lerner College of Medicine & Queen Mary University of London.
Papers
More filters
Journal ArticleDOI
Axonal transection in the lesions of multiple sclerosis.
TL;DR: Transected axons are common in the lesions of multiple sclerosis, and axonal transection may be the pathologic correlate of the irreversible neurologic impairment in this disease.
Journal ArticleDOI
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
Lawrence Jacobs,Diane Cookfair,Richard A. Rudick,Robert M. Herndon,John R. Richert,Andres M. Salazar,J. S. Fischer,Donald E. Goodkin,Carl V. Granger,Jack H. Simon,John J. Alam,David M. Bartoszak,Dennis Bourdette,Jonathan Braiman,Carol M. Brownscheidle,Michael E. Coats,Stanley Cohan,David S. Dougherty,R. P. Kinkel,Michele Mass,Frederick Munschauer,Roger L. Priore,Patrick M. Pullicino,Barbara J. Scherokman,Bianca Weinstock-Guttman,Ruth H. Whitham +25 more
TL;DR: Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.
Journal ArticleDOI
Defining the clinical course of multiple sclerosis: The 2013 revisions
Fred D. Lublin,Stephen C. Reingold,Jeffrey A. Cohen,Gary Cutter,Per Soelberg Sørensen,Alan J. Thompson,Jerry S. Wolinsky,Laura J. Balcer,Brenda Banwell,Frederik Barkhof,Bruce F. Bebo,Peter A. Calabresi,Michel Clanet,Giancarlo Comi,Robert J. Fox,Mark S. Freedman,Andrew D. Goodman,Matilde Inglese,Ludwig Kappos,Bernd C. Kieseier,John A. Lincoln,Catherine Lubetzki,Aaron E. Miller,Xavier Montalban,Paul O'Connor,John Petkau,Carlo Pozzilli,Richard A. Rudick,Maria Pia Sormani,Olaf Stüve,Emmanuelle Waubant,Chris H. Polman +31 more
TL;DR: Refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression are proposed and strategies for future research to better define phenotypes are outlined.
Journal ArticleDOI
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Richard A. Rudick,WH Stuart,Peter A. Calabresi,Christian Confavreux,Steven L. Galetta,Ernst Wilhelm Radue,Fred D. Lublin,Bianca Weinstock-Guttman,Daniel Wynn,F Lynn,Michael Panzara,Alfred Sandrock +11 more
TL;DR: Natalizumab added to interferon beta-1a was significantly more effective in patients with relapsing multiple sclerosis, and additional research is needed to elucidate the benefits and risks of this combination treatment.
Journal ArticleDOI
Development of a multiple sclerosis functional composite as a clinical trial outcome measure
Gary Cutter,Monika Baier,Richard A. Rudick,Diane Cookfair,J. S. Fischer,John Petkau,Karl Syndulko,Brian G. Weinshenker,Jack P. Antel,Christian Confavreux,George W. Ellison,Fred D. Lublin,Aaron E. Miller,Stephen M. Rao,Stephen C. Reingold,Alan J. Thompson,Ernest Willoughby +16 more
TL;DR: A composite measure encompassing the major clinical dimensions of arm, leg and cognitive function was identified and termed the multiple sclerosis functional composite (MSFC), suggesting that the MSFC is more sensitive to change than the EDSS.